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Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancerrelated deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased
by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium
(CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe
COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among
patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of
COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–
recently treated B-lymphoid malignancies, after adjustment for cancer status and several other
prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy
are at uniquely high risk for severe COVID-19.

ABSTRACT

SIGNIFICANCE: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent
risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies
targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies.
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Patients Recently Treated for B-lymphoid
Malignancies Show Increased Risk of Severe
COVID-19

Rubinstein et al.

INTRODUCTION

current or prior history of cancer who have developed presumed or laboratory-confirmed COVID-19. One of the largest databases of its kind, the CCC19 registry, enables granular
analysis of the independent association of clinical risk factors
with outcomes in this unique patient population, including controlled analyses not possible in smaller databases or
those generated solely from electronic health records. The
CCC19 framework facilitates relatively robust analysis of the
independent association of B-lymphoid malignancy diagnoses and B-lymphoid malignancy therapies with COVID-19–
specific outcomes. Using data derived from the CCC19 registry, we sought to investigate the impact of anticancer therapy on COVID-19 outcomes in patients with B-lymphoid
malignancies. We hypothesized that B-lymphoid malignancies themselves as well as therapies for B-lymphoid malignancies would be independently associated with increased
COVID-19 severity.

The disease caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), known as coronavirus disease
2019 (COVID-19), was classified as a pandemic by the World
Health Organization (WHO) in February 2020. As of December 19, 2021, more than 273 million cases have been reported
worldwide, with more than 5.3 million deaths (https://apps.
who.int/iris/bitstream/handle/10665/338703/nCoV-weeklysitrep12Jan21-eng.pdf). The effects of the pandemic have
been especially profound on high-risk patients, including
patients with cancer. Of patients with cancer, those with
hematologic malignancies are at particularly high risk of
severe viral infections due to disease-related myelosuppression, deficits in humoral and cellular immunity, as well as the
immunosuppressive effects of therapy (1–4). Multiple studies have reported a relatively high risk of severe COVID-19
and mortality for patients with hematologic malignancies,
although the precise risks reported are highly variable and
depend on factors related to the patient’s other comorbidities, specific type of cancer and cancer therapy, and external
factors such as local epidemiology and resources available in
health care systems (5–10). Patients with B-lymphoid malignancies in particular have been documented to have inferior
outcomes, likely due to the humoral and cellular immune
dysfunction associated with these cancers (11–14).
The impact of drug therapies for B-lymphoid malignancies
on COVID-19 outcomes is not clear. Early in the pandemic,
some therapies that are widely used to treat lymphoid malignancies, particularly Bruton’s tyrosine kinase (BTK) inhibitors, were hypothesized to have efficacy as anti–COVID-19
therapies, but clinical trials of these agents did not demonstrate a clear benefit (9, 15). The association between cancer
treatment and risk of severe COVID-19 has varied across
studies. Some studies have demonstrated an increased risk
of severe COVID-19, whereas other studies have demonstrated no association after adjustment for other pertinent
risk factors such as age, sex, and relevant comorbidities (16,
17). Although dedicated studies of patients with B-lymphoid
malignancies have shown poor outcomes for this population
as a whole, these studies have not demonstrated an increase
in COVID-19–associated mortality or severity in patients who
have recently received anticancer drug therapy after adjustment for other important risk factors, such as disease control
(11, 13). However, these studies were potentially inadequately
powered to demonstrate an effect.
The COVID-19 and Cancer Consortium (CCC19) is an
international consortium that collects data on patients with
27
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RESULTS
Patient Characteristics
A total of 10,380 records from the CCC19 registry were
evaluated. After exclusion criteria were applied, a total of
8,759 records were included in the primary analysis (Supplementary Fig. S1). Most (n = 7,509, 86%) of the cohort
had follow-up information after diagnosis of COVID-19 of
30 days or greater, and were symptomatic at presentation
(n = 7477, 85%). The median age of the included cohort
was 65 years (interquartile range: 55–74), and the majority
(n = 4596, 53%) were female. Approximately half of the cohort
was non-Hispanic White, while non-Hispanic Black patients
represented 18% and Hispanic patients represented 16%.
Similar proportions of patients were diagnosed with cancer
within 1 year prior to COVID-19 (n = 2,397, 26%), within 5
years prior to COVID-19 (n = 3,258, 37%), and greater than or
equal to 5 years prior to COVID-19 (n = 2,786, 32%).
The most common cancer diagnoses among the control groups of patients without B-lymphoid malignancies
(n = 7,764) were breast adenocarcinoma (n = 1,622), prostate
adenocarcinoma (n = 1,009), and non–small cell lung cancer (n = 519). Eleven percent (n = 995) of the entire cohort
had a B-lymphoid neoplasm. Approximately half of these
(n = 499) had low-grade non-Hodgkin lymphoma [chronic
lymphocytic leukemia (CLL) included]. The most common
B-lymphoid malignancy diagnosis was CLL (n = 255). Of the
patients with B-lymphoid malignancies, approximately half
had received systemic therapy within one year of COVID-19
Note: Supplementary data for this article are available at Blood Cancer
Discovery Online (https://bloodcancerdiscov.aacrjournals.org/).
S.M. Rubinstein, D. Bhutani, R.C. Lynch, J.L. Warner, and M.A. Thompson
contributed equally to this article.
Corresponding Author: Samuel M. Rubinstein, University of North Carolina
Chapel Hill, 170 Manning Drive, Campus Box 7305, Chapel Hill, NC 27599.
Phone: 919-966-4431; Fax: 919-966-6735; E-mail: Samuel_rubinstein@
med.unc.edu
Blood Cancer Discov 2022;3:1–13
doi: 10.1158/2643-3230.BCD-22-0013

©2022 American Association for Cancer Research
AACRJournals.org

Downloaded from http://aacrjournals.org/bloodcancerdiscov/article-pdf/doi/10.1158/2643-3230.BCD-22-0013/3109156/bcd-22-0013.pdf by Henry Ford Hospital user on 28 April 2022

RESEARCH BRIEF

Impact of B-cell Malignancy Therapy on COVID-19 Outcomes

diagnosis (n = 516, 52%), and half had not (n = 479, 48%).
These were similar proportions to the patients without
B-lymphoid malignancies [n = 3,653 (46%) treated within
a year, 4,111 (54%) not treated within a year]. Additional
patient characteristics are shown in Table 1 and Supplementary Table S1.

Patient Outcomes

There was a statistically significant prespecified interaction
between the study populations of interest and cancer status.
Compared to patients in the nonrecently treated control
population in remission, patients with nonrecently treated
B-lymphoid malignancies experienced increased COVID-19
severity if the malignancy was active but stable or responding (AOR, 1.80; 95% CI, 1.16–2.80); the interaction effect for
patients with active and progressing B-lymphoid malignancies off therapy was not statistically significant (AOR, 1.48;
95% CI, 0.70–3.10). Cancer status did not appear to further
modify the statistically significant association of recently
treated B-lymphoid malignancies with increased COVID-19
severity (Fig. 1; Table 2).
Analyses of individual secondary outcomes revealed
increased rates of hospitalization both in patients recently
treated for B-lymphoid malignancies (AOR, 2.84; 95% CI,
1.67–4.85) and patients with nonrecently treated B-lymphoid
malignancies (AOR, 1.36; 95% CI, 1.00–1.85) compared with
the nonrecently treated control population. ICU utilization
was increased in patients recently treated for B-lymphoid
malignancies (AOR, 2.12; 95% CI, 1.07–4.22), but not in
patients with nonrecently treated B-lymphoid malignancies
(AOR, 1.12; 95% CI, 0.78–1.61). There was no independent
association with either category of patients with B-lymphoid
malignancies and increased 30-day mortality or rates of
mechanical ventilation (Supplementary Tables S4–S6).
Sensitivity analyses limited to patients with complete
30-day follow-up information and symptomatic COVID-19
did not reveal significant differences (Supplementary
Tables S7 and S8). Of note, after adjustment for convalescent
plasma receipt, patients with treated B-lymphoid malignancies no longer had increased COVID-19 severity compared
with patients with nonrecently treated B-lymphoid malignancies (AOR, 1.34; 95% CI, 0.85–2.11; Supplementary Table S9).

Outcomes for Patients Stratified by
Therapeutic Regimen
For the 516 patients recently treated for B-lymphoid
malignancies, a specific regimen received was extractable
in 436 (84%). COVID-19 severity was generally high in this
group of patients. The outcomes for patients with the most
widely used regimens are shown in Fig. 2. COVID-19 severity
was particularly high in patients who recently received BTK
inhibitor monotherapy and in patients receiving combinations of anti-CD20 mAbs and alkylators, with each group
demonstrating 20% mortality at 30 days. More data on the
most recent regimens received in these patients are provided
in Supplementary Table S10.

Outcomes for Patients Developing COVID-19 after
COVID-19 Vaccinations
In total, 128 patients in this cohort had an infection following full or partial COVID-19 vaccination. A relatively
small number of breakthrough infections after COVID-19
vaccination were recorded in patients recently treated for
B-lymphoid malignancies (n = 15) and in patients with nonrecently treated B-lymphoid malignancies (n = 6). Of the
patients recently treated for B-lymphoid malignancies who
developed COVID-19 after COVID-19 vaccination, 12 (80%)
required hospitalization.
MAY 2022
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Of the 8,759 patients in the cohort overall, the majority (n = 4,840, 55%) required hospitalization during their
COVID-19 illness; patients with B-lymphoid malignancy had
a higher hospitalization rate (n = 659, 67%). Mortality in the
cohort overall was 12%, with mortality of 13% in patients with
B-lymphoid malignancies. Across malignancies, outcomes
were worst for patients with chronic lymphocytic leukemia
(CLL), 72% of whom required hospitalization and 19% of
whom died. Mortality was 21% for patients diagnosed with
COVID-19 during the first four months of 2020, declining
to 10% by the middle four months and 8% by the last four
months of 2020. Mortality was particularly high in patients
with malignancies that were either active and progressing
(26%) or who had an ECOG performance status of 2 or
greater (31%). Additional descriptive outcomes are demonstrated in Supplementary Table S2.
The cohort was divided into four mutually exclusive
groups: (i) patients with solid tumors or non–B-lymphoid
hematologic malignancies not treated for cancer within
one year of COVID-19 diagnosis (“nonrecently treated control population”); (ii) patients with B-lymphoid malignancies not treated for cancer within one year of COVID-19
diagnosis (“patients with nonrecently treated B-lymphoid
malignancies”); (iii) patients with solid tumors or non–
B-lymphoid hematologic malignancies treated for cancer
within one year of COVID-19 diagnosis (“recently treated
control population”), and (iv) patients with B-lymphoid
malignancies treated within a year of diagnosis (“patients
recently treated for B-lymphoid malignancies”). In the primary analysis, compared with the population of patients
with nonrecently treated B-lymphoid malignancies, COVID19 severity was similar in the nonrecently treated control
population (AOR, 0.86; 95% CI, 0.67–1.22), and the recently
treated control population had reduced COVID-19 severity (AOR, 0.65; 95% CI, 0.47–0.89). Central to this analysis, patients recently treated for B-lymphoid malignancies
had increased COVID-19 severity compared with patients
with nonrecently treated B-lymphoid malignancies (AOR,
1.98; 95% CI, 1.27–3.08) as well as to both the nonrecently
treated and recently treated control populations. Beyond
these primary findings, multivariable analysis for the entire
cohort revealed increasing COVID-19 severity with increasing age, male sex, progressing malignancy, obesity, Hispanic
ethnicity and non-Hispanic Black race, and diagnosis of
cancer within one year prior to COVID-19 diagnosis. ECOG
performance status of 2 or greater and increasing modified Klabunde comorbidity index were also associated with
increased COVID-19 severity. Calendar time had a statistically significant association with COVID-19 severity after
adjustment, with greatest mortality during the initial phase
of the pandemic in the first four months of 2020 (Fig. 1;
Supplementary Table S3).
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Table 1. Baseline patient characteristics

Characteristics

B-lymphoid malignancies
off therapy
(n = 479)

Recently treated
control
(n = 3653)

Recently treated
B-lymphoid malignancies
(n = 516)

71% (2901)
14% (555)
8% (311)
8% (342)
0% (<5)
67 (57–77)

56% (266)
29% (137)
6% (31)
9% (44)
0% (<5)
63 (52.5–74)

23% (837)
47% (1706)
21% (777)
9% (326)
0% (7)
63 (53–72)

27% (137)
45% (232)
16% (81)
13% (66)
0% (<5)
62 (47–73)

50% (2073)
49% (2034)

43% (204)
57% (275)

58% (2108)
42% (1544)

41% (211)
59% (304)

33% (1360)
17% (717)
12% (513)
37% (1517)
<1% (<5)

41% (194)
20% (97)
10% (48)
29% (140)
<1% (<5)

34% (1225)
35% (1265)
16% (576)
16% (576)
<1% (11)

30% (157)
38% (196)
15% (75)
17% (87)
<1% (<5)

52% (2119)
46% (1889)
3% (103)
2 (1–3)

58% (277)
38% (183)
4% (19)
2 (1–3)

53% (1953)
43% (1569)
4% (131)
1 (1–2)

59% (305)
37% (190)
4% (21)
1 (1–2)

25% (1039)
40% (1653)
20% (832)
14% (555)
1% (23)
<1% (9)

26% (125)
43% (205)
19% (90)
12% (58)
<1% (<5)
<1% (<5)

23% (829)
41% (1505)
20% (746)
15% (534)
1% (23)
<1% (16)

27% (137)
37% (191)
20% (102)
15% (79)
1% (<5)
<1% (<5)

56% (2302)
13% (514)
19% (787)
11% (449)
1% (59)

58% (276)
15% (71)
14% (66)
12% (59)
1% (7)

49% (1801)
19% (703)
18% (669)
11% (401)
2% (79)

50% (259)
24% (122)
14% (70)
12% (61)
1% (<5)

60% (2460)
40% (1636)
<1% (15)

66% (317)
34% (161)
<1% (<5)

63% (2294)
36% (1329)
1% (30)

62% (322)
37% (191)
<1% (<5)

31% (1278)
32% (1333)
15% (597)
19% (763)
3% (140)

39% (187)
25% (118)
15% (70)
17% (82)
5% (22)

41% (1482)
20% (746)
17% (607)
17% (625)
5% (193)

42% (219)
21% (106)
18% (95)
15% (78)
3% (18)

1% (50)
30% (1213)
3% (111)
67% (2737)

1% (6)
27% (129)
3% (15)
69% (329)

2% (57)
29% (1065)
3% (102)
66% (2429)

3% (15)
30% (155)
2% (100)
65% (336)

NOTE: These are intended to avoid potential identification of patients based on relatively rare permutations of variables. To this end, data are only
presented for categories in which displaying these outcome data is feasible without violation of this standard, to protect patient privacy.
Abbreviations: ECOG, Eastern Cooperative Oncology Group. Counts less than 5 are not presented pursuant to CCC19 consortium publication
standards; NED, no evidence of disease.

OF4 | BLOOD CANCER DISCOVERY

MAY 2022

AACRJournals.org

Downloaded from http://aacrjournals.org/bloodcancerdiscov/article-pdf/doi/10.1158/2643-3230.BCD-22-0013/3109156/bcd-22-0013.pdf by Henry Ford Hospital user on 28 April 2022

Cancer status
Remission/NED
Active, stable or responding
Active, progressing
Unknown
Missing
Age [years, median (IQR)]
Sex
Female
Male
ECOG performance status
Zero
One
Two or greater
Unknown
Missing
Smoking status
Never
Current or former
Missing
Modified Charlson Comorbidity
index (median, IQR)
Timing of COVID-19 diagnosis
Jan–Apr 2020
May–Aug 2020
Sep–Dec 2020
Jan–Apr 2021
May–Aug 2021
Missing
Race
Non-Hispanic White
Hispanic
Non-Hispanic Black
Other
Missing
Obesity
Not obese
Obese
Missing
Region
U.S. Northeast
U.S. Midwest
U.S. South
U.S. West
Other
Vaccination status
Any vaccine before COVID-19
No vaccine before COVID-19
Unknown
Missing

Nonrecently
treated control
(n = 4111)

Impact of B-cell Malignancy Therapy on COVID-19 Outcomes

RESEARCH BRIEF
(ref = Patients with B-lymphoid malignancies off therapy)

–2

–1.5

–1

–0.5
0
0.5
Log(OR) (95% CI)

1

1.5

2

Figure 1. Factors associated with COVID-19 severity. Forest plot visualization of the independent association of the covariates in the primary

analysis with COVID-19 severity. Associations are represented as the log of the odds ratio of COVID-19 severity. Interaction terms are indicated with
an asterisk.

DISCUSSION
COVID-19 poses unique risks to patients with B-lymphoid
malignancies. These patients are recognized to be at high
risk of morbidity and mortality in the context of respiratory
viruses. Potential etiologies include impaired host immunity
from effects of the malignancies and treatments, as well as
a high burden of noncancer comorbidities, and low rates
of seroconversion to relevant vaccinations (18–21). Indeed,

seroconversion after COVID-19 vaccination has been found
to be impaired in this patient population, perhaps more so
in the setting of several lymphocytotoxic therapies, including anti-CD20 mAbs and BTK inhibitors (18–22). As such,
COVID-19 remains a particularly salient concern even with
widely available vaccinations, and deeper understanding of
factors associated with COVID-19 severity in this population
remains of paramount importance to inform prevention and
management strategies.
MAY 2022
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Study populations
Nonrecently treated control population
Recently treated control population
Patients recently treated for B-lymphoid malignancies
Cancer status (ref = Remission/NED)
Active, stable/responding
Active, progressing
Unknown
Age
Every 10-year increase
Sex (ref = Female)
Male
ECOG performance status (ref = zero)
One
Two+
Unknown
Smoking status (ref = never)
Current or former
Modified Charlson Comorbidity index
Every 1-point increase
Trimester of COVID-19 diagnosis (ref = January 2020 – April 2020)
May 2020–August 2020
September 2020–December 2020
January 2021–April 2021
May 2020–August 2020
Race (ref = non-Hispanic white)
Hispanic
Non-Hispanic Black
Other
Obesity (ref = not obese)
Obese
Region (ref = US Northeast)
U.S. Midwest
U.S. South
U.S. West
Non-U.S.
Timing of cancer diagnosis (ref = greater than 5 years prior to COVID_19 diagnosis)
Within 1 year of COVID-19 diagnosis
Between one and five years prior to COVID-19 diagnosis
Negative control population: Active, stable/responding*
Positive control population: Active, stable/responding*
Patients recently treated for B-lymphoid malignancies: Active, stable/responding*
Negative control population: Active, progressing*
Positive control population: Active, progressing*
Patients recently treated for B-lymphoid malignancies: Active, progressing*
Negative control population: Unknown*
Positive control population: Unknown*
Patients recently treated for B-lymphoid malignancies: Unknown*

Rubinstein et al.
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Table 2. Results of regression analysis for primary outcome: COVID-19 severity (N = 8759)

Characteristics

Multivariable AOR (95% CI)

Study populations (ref = Patients with nonrecently treated B-lymphoid malignancies)
1.16 (0.90–1.49)

Recently treated control population

0.75 (0.61–0.93)

Patients recently treated for B-lymphoid malignancies

2.30 (1.58–3.36)

Cancer status (ref = remission/NED)
Active, stable/responding

0.86 (0.70–1.06)

Active, progressing

2.67 (2.05–3.48)

Unknown

1.41 (1.10–1.81)
1.29 (1.24–1.35)

Age (every 10-year increase)
Sex (ref = Female)

1.38 (1.23–1.54)

Male
ECOG Performance Status (ref = zero)

1.80 (1.56–2.08)
3.89 (3.27–4.63)
1.73 (1.50–2.00)

One
Two or greater
Unknown
Smoking status (ref = never)

1.20 (1.07–1.34)

Current or former

1.18 (1.13–1.22)

Modified Charlson Comorbidity Index
Trimester of COVID-19 diagnosis (ref = January 2020–April 2020)
May 2020–Aug 2020

0.54 (0.47–0.62)

Sep 2020–Dec 2020

0.46 (0.39–0.55)

Jan 2021–Apr 2021

0.42 (0.35–0.50)

May 2021–Jun 2021

0.82 (0.43–1.56)

Race (ref = non-Hispanic white)
Hispanic

1.41 (1.20–1.67)

Non-Hispanic Black

1.53 (1.33–1.76)

Other

1.19 (0.96–1.47)

Obesity (ref = not obese)
1.19 (1.06–1.34)

Obese
Region (ref = US Northeast)
U.S. Midwest

0.86 (0.75–0.98)

U.S. South

0.86 (0.73–1.01)

U.S. West

0.61 (0.51–0.73)

Non-U.S.

1.05 (0.76–1.44)

Timing of cancer diagnosis (ref = Greater than 5 years prior to COVID-19 diagnosis)
Within 1 year of COVID-19 diagnosis

1.06 (0.91–1.24)

Between one and five years prior to COVID-19 diagnosis

0.94 (0.82–1.09)

Interaction terms (ref = patients with nonrecently treated B-lymphoid malignancies in remission/NED)
Negative control population x active and stable/responding cancer

1.80 (1.16–2.80)

Positive control population x active and stable/responding cancer

1.57 (1.16–2.12)

Patients recently treated for B-lymphoid malignancies x active and stable/responding cancer

0.78 (0.46–1.31)

Negative control population x active and progressing cancer

1.48 (0.70–3.10)

Positive control population x active and progressing cancer

1.02 (0.71–1.46)

Patients recently treated for B-lymphoid malignancies x active and progressing cancer

0.76 (0.38–1.54)

Negative control population x unknown cancer status

1.94 (1.05–3.58)

Positive control populationx unknown cancer status

1.69 (1.13–2.51)

Patients recently treated for B-lymphoid malignancies x unknown cancer status

0.77 (0.36–1.64)

NOTE: An OR > 1 indicates increased risk of high COVID-19 severity; Odds Ratio < 1 indicates decreased risk of high COVID-19 severity.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NED, no evidence of disease.
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COVID-19 severity by regimen
Anti-CD20 monotherapy (n = 39)

BTKi monotherapy (n = 75)

EPOCH-like regimens (n = 16)

Anti-CD20 + alkylator (n = 20)

Outpatient
Inpatient
Inpatient + O2
ICU
ICU + mech. vent.
Death

CHOP-like regimens (n = 39)

0.0

0.2

0.4
0.6
0.8
Proportion of patients

1.0

Figure 2. Descriptive outcomes for patients receiving various regimens. Bar plot demonstrating rates of the ordinal outcome for patients recently

treated for B-lymphoid malignancies stratified by the type of regimen received. No statistical comparisons between these groups were undertaken due
to small numbers of patients in some of these categories, and these data are presented for the purposes of description only. More data on regimens
received by the patients in this study are presented in the supplement.

Prior studies showed high rates of COVID-19 severity in
patients with B-lymphoid malignancies, but no increase in
COVID-19 severity or mortality associated with treatment
of B-lymphoid malignancies. However, these studies were
smaller than the current study and did not compare outcomes
with untreated control populations (11, 14, 23, 24). This is
the largest study of patients specifically with B-lymphoid
malignancies and COVID-19 to date, with a cohort of 995
of such patients. Using multiple internal control populations, we demonstrated that compared with both treated
and untreated control populations of patients with other
malignancies, patients recently treated for B-lymphoid malignancies experienced increased COVID-19 severity after adjustment. Patients recently treated for B-lymphoid malignancies
also had increased rates of hospitalization and ICU utilization compared with the control populations. These findings
were stable to retesting the hypothesis under several preplanned sensitivity analyses in distinct study subpopulations.
Although this is a retrospective study, there are clinical
implications. While the association of therapy for B-lymphoid
malignancies with increased COVID-19 severity is troublesome, we note that the association of progressive malignancy
with COVID-19 severity is also independently associated with
increased COVID-19 severity. This is concordant with prior
publications from the CCC19 and other groups (17, 25, 26).
The etiology of this relationship is not clear from the data; it
may be that patients with progressive malignancy are disproportionately deferring aggressive care in the setting of severe
COVID-19, or that improved control over the primary malignancy results in reduced disease-related immunosuppression.
In any case, these data do not support deferring highly effective anticancer therapies. A study of the effects of deferring

chemotherapy in the setting of COVID-19 is not within the
purview of CCC19. Our findings do suggest that increased
potential for severe COVID-19 should enter into informed
consent discussions of treatments for B-lymphoid malignancies. Clinicians may consider temporarily delaying therapy
in situations where community transmission is high, or to
allow for patients to be fully vaccinated. The increased risk of
severe COVID-19 should factor into risk–benefit discussions
about using long-term anti-CD20 maintenance therapies in
scenarios where that approach is not associated with a proven
overall survival benefit. Both individual and population-wide
prevention strategies will remain of paramount importance
to protect this vulnerable population.
Although during the later part of the study period COVID19 vaccinations became widely available, the number of infections that occurred following vaccination was too small
to analyze the independent association of vaccination with
COVID-19 severity in patients with B-lymphoid malignancies, and any effect from boosters is not yet observed within
the timeframe. Many patients recently treated for B-lymphoid
malignancies will have impaired responses and immunity
following COVID-19 vaccination, and these results likely
remain salient to those patients. However, it is not possible
to say with the clinical data available to the CCC19 registry
whether those patients with B-cell malignancy who develop
breakthrough infection are also those with the impaired
response; prior studies have shown that even patients with
an impaired antibody response can manifest T cell–mediated
immunity; focused prospective studies are better equipped
to answer this ongoing question (27). Although responses
to primary vaccination series in this patient population have
been shown to be suboptimal, there are data suggesting that
MAY 2022
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with B-lymphoid malignancies did not experience increased
COVID-19 severity than patients in the nonrecently treated
control population in general, patients with nonrecently
treated B-lymphoid malignancies with active and stable or
responding malignancies experienced increased COVID-19
severity. This effect was not statistically significant for
patients with active and progressive B-cell malignancies off
therapy, although the number of such patients may have
been too small to observe an independent effect (n = 31).
The observation that patients with nonrecently treated
B-lymphoid malignancies in this study did not experience
increased COVID-19 severity compared to control populations may have been driven by the fact that most of these
patients (n = 266, 56%) were in remission, and therefore had
minimal or no disease-related immunosuppression.
Of note, a small number of patients recently treated for
B-lymphoid malignancies (n = 29, 6%) had been treated with
transplantation or cellular therapy within a year of developing COVID-19; this group had a mortality of 20%. Although
the study is too small to study that population in a dedicated
capacity, it may be that recent stem cell transplantation or
cellular therapy have unique modifying effects on the risk
of severe COVID-19; the numbers of patients receiving these
interventions in this cohort were too small to analyze this
independent association. Such analyses should be a focus of
future work as this and other disease-specific registries continue to expand (37).
This study has important limitations. This is a registry
analysis, and although there may be some clinical implications of the findings, these data are primarily useful for
hypothesis-generation. Furthermore, as a registry analysis,
there is inherent selection bias in that patients with very
mild disease may not come to the attention of sites reporting
to the registry. As such, it is likely that the study population
has greater COVID-19 severity than the general population of patients with cancer and COVID-19. With that said,
this study includes a greater proportion of nonhospitalized
patients than other registry studies and may have improved
generalizability as a result. To maximize sample size, the
study populations are heterogeneous, including with respect
to most recent therapeutic exposures, which limits the generalizability of the findings. There are significant differences
between the timing of COVID-19 diagnosis in this study and
the epidemiology of the pandemic in the general population, with relative overrepresentation of diagnoses earlier
in the pandemic. This may be due to high vigilance against
COVID-19 in this patient population resulting in improved
prevention over time but may also reflect reporting bias. As
the ordinal outcome of COVID-19 severity includes metrics
such as hospitalization and ICU admission, it is possible
that patients with B-lymphoid malignancies are preferentially admitted to relatively higher level of care due to their
malignancy as opposed to intrinsic features of COVID-19.
As increased mechanical ventilation was observed in both
patients recently treated for B-lymphoid malignancies and
patients with nonrecently treated B-lymphoid malignancies
this does not likely explain all of the increased COVID-19
severity observed in this population but may explain some
of the findings. Conversely, a subset of patients with B-lymphoid malignancies receive their treatment as an inpatient
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boosters significantly increase vaccine efficacy in patients
with B-lymphoid malignancies (21). These data highlight the
importance of optimal prevention of COVID-19 in this population, including widespread deployment of boosters. Many
health care systems are having to ration critical COVID-19
therapeutics, such as sotrovimab, tixagevimab/cilgavimab,
and oral antivirals, given critical shortages. Our data suggest that patients recently treated for B-lymphoid malignancies should be prioritized to receive these therapies. More
study of additional strategies, such as mAb or oral antiviral
prophylaxis for high-risk exposures, are needed to reduce the
morbidity of COVID-19 in this population.
The study period (March 2020–June 2021) ended prior to
the high prevalence of the delta and omicron SARS-CoV-2 variants. At the time of publication of this manuscript, the omicron variant is most prevalent in the United States (https://
covid.cdc.gov/covid-data-tracker/#variant-proportions).
Although this variant may result in milder disease than
the wild type coronavirus, the degree to which that finding is due to intrinsic properties of the omicron variant
or prior immunity is not clear (28). As patients treated for
B-lymphoid malignancies have impaired humoral immunity
and have been shown to have impaired response to vaccination, COVID-19 due to the omicron variant may not
be milder in this vulnerable population. It is also possible
that future variants will exhibit greater immune escape
potential and virulence than omicron. For these reasons,
these results remain relevant in the current state of the
COVID-19 pandemic.
In this study, the point estimate for mortality in patients
with B-lymphoid malignancies and COVID-19 (13%) is somewhat lower than that in other reported studies, which have
demonstrated mortalities for patients with hematologic
malignancies in general and COVID-19 between 28 and 37%
(7, 8, 29). The patients included in many of these studies
were diagnosed relatively early in the pandemic, whereas
the majority of the patients in this study were diagnosed
after May 2020. As was shown in this and other studies,
the outcomes for patients with cancer and COVID-19 have
been improving throughout the pandemic (17, 30). During
the early periods, many health care systems were under significant strain due to surging cases, in many cases requiring
rationing of care. In addition, the therapeutic paradigm for
COVID-19 itself has changed since the onset of the pandemic
in ways which are beneficial to patients with hematologic
malignancies, in that the widespread off-study use of ineffective or even harmful COVID-19 therapies (31, 32) has been
replaced by COVID-19 therapies with proven benefit (33–35).
In the case of mAbs, it may be the case that these therapies
abrogate some of the unique risk that COVID-19 poses to
patients with B-lymphoid malignancies given the relative
inability of these patients to produce neutralizing antibodies
to COVID-19 (36).
Our finding that patients with nonrecently treated B-lymphoid malignancies did not experience increased COVID-19
severity compared with the nonrecently treated control population initially seems at odds with the wider literature.
However, analysis of interaction effects suggested that the
association of a B-lymphoid malignancy with COVID-19
severity was modified by cancer status. Although patients
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METHODS
Study Design and Population
The origin, methodology for patient accrual, and data structure
used by the CCC19 registry are described elsewhere (38–40). The
CCC19 data are collected and managed using REDCap software
hosted at Vanderbilt University Medical Center (Nashville, TN;
refs. 41, 42). REDCap is developed and supported by the Vanderbilt
Institute for Clinical and Translational Research grant support (UL1
TR000445 from NCATS/NIH). This study was partly supported by
grants from the NCI (grant number P30CA068485 to Vanderbilt
University Medical Center). Reports were accessed for patients diagnosed with COVID-19 from March 17, 2020 through June 13, 2021.
Included patients were adults with cancer diagnoses (including
cancers in remission) greater than 18 years of age with laboratoryconfirmed diagnosis of SARS-CoV-2. Laboratory confirmation can
include PCR, antigen testing/ELISA, antibodies to SARS-CoV-2, or
any other test that would be consistent with a current or prior SARSCoV-2 infection. Patients with precursor hematologic neoplasms
[e.g., monoclonal gammopathy of uncertain significance (MGUS),
monoclonal B-lymphoid lymphocytosis (MBL)] were excluded. The
cohort captures cancer diagnosis by a terminology derived from
the NCI Thesaurus. Records with incomplete outcome information
such that the primary outcome could not be determined, quality
scores greater than 4 (described below) indicative in general of
high missingness of data or excessive unknowns, and missing data
on the timing of cancer therapy receipt were also excluded from
the analysis.
The CCC-19 uses a quality scoring system to determine the suitability of records for inclusion in analyses. A score greater than 5 was
considered insufficient for inclusion in the analysis presented. Scores
are tabulated as follows:

Minor problems (+1 point per problem):
ADT missing/unknown (prostate cancers only)
Biomarkers missing/unknown (breast cancers only)
ICU admission missing/unknown
Hospitalization missing/unknown
Mechanical ventilation missing/unknown
O2 ever needed missing/unknown
Days to death missing/unknown
Cancer status unknown
ECOG PS unknown
Missing cancer drug names for patients on systemic anticancer
treatment
Missing or unknown categorical lab values if labs were drawn.
Moderate problems (+3 points per problem):
Cancer status missing
ECOG PS missing
Death status missing/unknown
Baseline COVID-19 severity missing/unknown
Should have 30-day follow-up but doesn’t
Major problems (+5 points per problem)
High levels of missingness
High levels of unknowns
The study was exempt from institutional review board (IRB)
review (VUMC IRB#200467) and approved by IRBs at participating
sites according to local institutional policies. A list of participants
indexed by institution is included in Supplementary Appendix S1.
The CCC19 study is registered on ClinicalTrials.gov (NCT04354701)
and is ongoing. The funding sources had no role in the writing of the
manuscript or the decision to submit it for publication.

Outcomes
The primary outcome was an ordinal scale of COVID-19 severity
based on each patient’s most severe reported disease status graded as
(i) not meeting any of the other severity outcomes; (ii) hospitalized
without supplemental oxygen; (iii) hospitalized with supplemental
oxygen; (iv) admitted to an intensive care unit (ICU) without mechanical ventilation; (v) mechanical ventilation, and (vi) death from any
cause within 30 days of COVID-19 diagnosis. A similar ordinal
outcome has been used in prior publications from the CCC19 (17,
43) Secondary analyses with primary outcomes of 30-day all-cause
mortality, ICU requirement, and mechanical ventilation requirement
were conducted.

Subpopulations of Interest and Covariates
To test the hypothesis that B-lymphoid malignancies and associated anti-cancer drug therapies for lymphoid malignancies were independently associated with increased COVID-19 severity, we divided
the cohort into four mutually exclusive groups: (i) patients with solid
tumors or non-B-lymphoid hematologic malignancies not treated for
cancer within one year of COVID-19 diagnosis (“nonrecently treated
control population”); (ii) patients with B-lymphoid malignancies not
treated for cancer within one year of COVID-19 diagnosis (“patients
with nonrecently treated B-lymphoid malignancies”); (iii) patients
with solid tumors or non-B-lymphoid hematologic malignancies
treated for cancer within one year of COVID-19 diagnosis (“recently
treated control population”), and (iv) patients with B-lymphoid
malignancies treated within a year of diagnosis (“patients recently
treated for B-lymphoid malignancies”). The one year timepoint was
chosen because B-cell repletion following anti-CD20 mAbs has been
shown to take up to 12 months (44–46).
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(e.g., DA-EPOCH-R and R-HyperCVAD) and may have been
diagnosed through routine screening protocols, and it is
possible that some patients would have been recorded as
hospitalized for COVID-19. As most patients who test positive for COVID-19 in this setting are discharged to quarantine and do not receive the planned chemotherapy, and a
sensitivity analysis excluding asymptomatic patients showed
similar results to the primary analysis, we do not think
this possibility impacted our findings. Although this is the
largest study of patients with B-lymphoid malignancies to
date, and sufficiently large to observe an association of
therapy in general on COVID-19 severity, the sample size
was insufficiently large to investigate the independent effects
of specific therapies, such as rituximab and ibrutinib, on
COVID-19 severity.
In conclusion, this analysis suggests that the general
population of patients with B-lymphoid malignancies is at
relatively increased risk of severe COVID-19, and that this
risk is further increased in the setting of recent anticancer
therapy. These findings provide important context for
informed consent discussions for patients with B-lymphoid
malignancies considering anticancer therapy, but do not
support deferring highly effective anticancer therapy in the
vast majority of cases. Individual patient scenarios need
to be considered in the context of community infectivity,
hospital resources, patient and tumor characteristics, and
disease response and prognosis. This remains a population of high need for improved primary prevention and
therapeutic strategies.
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Statistical Analysis
The primary objective of the analysis was to compare rates
of the primary outcome (COVID-19 severity) between the four
populations of interest (nonrecently treated control population, patients with nonrecently treated B-lymphoid malignancies, recently treated control population, patients recently treated
for B-lymphoid malignancies). A multivariable proportional odds
logistic regression model was applied, adjusting for the above
variables of interest. Before we conducted the logistic regression
analysis, we performed multiple imputations (with 10 imputations) for missing values of variables through additive regression,
bootstrapping, and predictive mean matching. Then, to reduce
the impact of confounders among the four populations in the
nonrandomized study, for each imputed dataset, we balanced the
distributions of covariates between the four populations through
inverse probability of treatment weighting (IPTW) by a multinomial logistic regression model. The reported AORs were the
average results of the logistic regression model applied to the
10 weighted imputed dataset. We hypothesized that after adjustment, patients with nonrecently treated B-lymphoid malignancies
would experience increased COVID-19 severity compared to both
nonrecently treated, and recently treated control populations, and
that patients recently treated for B-lymphoid malignancies would
experience the greatest COVID-19 severity among all four groups.
Regarding interaction terms, we hypothesized that for patients
who have not recently received therapy, the presence of active
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cancer would be associated with increased COVID-19 severity, and
cancers in remission would be associated with reduced COVID-19
severity. Similarly, multivariable binary logistic regression models along with multiple imputation and IPTW were applied in
secondary analyses.

Sensitivity Analyses and Descriptive Analyses
A number of prespecified sensitivity analyses testing the stability
of findings focused on the primary outcome in the group of interest were conducted. These were analyses restricted to patients with
completed 30-day follow up, patients with documented symptomatic
COVID-19, and adjustment for the receipt of convalescent plasma in
the subset of patients requiring hospitalization which in a previous
analysis of CCC19 data was shown to be associated with improved
30-day mortality for patients with hematologic malignancies and
COVID-19 (49). The procedure of analysis was the same as mentioned above: multiple imputation for missing values of variables,
IPTW for balance of covariate distributions, and multivariable proportional odds logistic regression analyses.
When available, free text descriptions of the most recent systemic
anticancer regimen received were extracted and normalized using
the HemOnc ontology (50). We described the differential impact of
specific regimens on COVID-19 severity. Representative examples of
how free text descriptions were abstracted into most recent systemic
anticancer regimen are demonstrated in Supplementary Table S11.
We also recorded vaccination status as follows: (i) any dose of
vaccine prior to COVID-19 diagnosis; (ii) no dose of vaccine prior
to COVID-19; (iii) unknown. Of note, much of this study period
occurred before COVID-19 vaccinations were available, and as the
CCC19 did not start collecting data on vaccination until vaccinations
were available, there is a high degree of missingness.
Counts less than 5 are not presented pursuant to CCC19 consortium publication standards. These are intended to avoid potential
identification of patients based on relatively rare permutations of
variables. To this end, data are only presented for categories in
which displaying these outcome data is feasible without violation
of this standard, to protect patient privacy. Analyses were performed in R version 4.0.3 (R Foundation for Statistical Computing,
Vienna, Austria), including the Hmisc, ipw, survey, and forestplot
extension packages.

Data Availability
The data dictionary for the CCC19 is publicly available on Github
(https://github.com/covidncancer/CCC19_dictionary). The data
generated in this study are not publicly available due to the possibility that patients with a rare combination of variables could
be reidentified, but are available upon reasonable request from
the corresponding author. All aggregate deidentified patient data
with site identifiers removed and geographical region of patient
residence masked to a level no smaller than U.S. Census Divisions
will be made publicly available for any purpose through the CCC19
website (https://www.ccc19.org) beginning 6 months and ending 72
months after publication of this article. These data will be displayed
with an interactive graphical tool, allowing for visual analytics of
the data. Individual deidentified patient data with site identifiers
removed and geographic region of patient residence masked to a
level no smaller than U.S. Census Divisions will be made available
to researchers who provide a methodologically sound proposal, and
whose proposed use of the data has been approved by an independent review committee identified for this purpose. External proposals
can be submitted beginning 6 months and up to 72 months after
publication of this article; the CCC19 is open to additional collaborators as well. All proposals should be directed to contact@
ccc19.org; to gain access, data requestors will need to sign a data
access agreement.
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Covariates of interest were identified a priori, and included the
following: age; sex; smoking status (ever smokers, never smokers); obesity; race/ethnicity; Eastern Cooperative Oncology Group
(ECOG) performance status; cancer status (remission/no evidence
of disease, active/stable or responding to treatment, active/progressing, unknown); timing of COVID-19 diagnosis; timing of
cancer diagnosis with respect to COVID-19 diagnosis; region (U.S.
West, U.S. Midwest, U.S. South, U.S. Northeast, and non-US); time
since cancer diagnosis with respect to COVID-19, and modified
Klabunde comorbidity index, which was treated as a continuous
variable (47). Race/ethnicity was categorized as Hispanic, nonHispanic Black, non-Hispanic White, or other. ECOG performance
status was categorized as 0, 1, or 2 or greater. Timing of COVID-19
diagnosis was categorized as follows: January–April 2020, May–
August 2020, September–December 2020, January–April 2021.
Time since cancer diagnosis with respect to COVID-19 diagnosis
was categorized as within a year of COVID-19 diagnosis, within five
years of COVID-19 diagnosis, and greater than five years prior to
COVID-19 diagnosis. The modified Klabunde comorbidity index
was derived from information collected in the CCC19 regarding
patient comorbidities, as data regarding hemiplegia and peptic
ulcer disease are not included in the CCC19, these elements of the
Klabunde index were omitted.
We accounted for interaction effects to better understand the
independent association of B-lymphoid malignancies, their therapies, and COVID-19 severity. In brief, interaction effects occur when
the impact of a clinical characteristic on an outcome depends on the
presence or absence of another characteristic. As such, we hypothesized that the association of B-lymphoid malignancy off therapy with
COVID-19 severity would depend on whether that malignancy was
active or inactive (48). To test this hypothesis, we added interaction
terms between the four populations of interest (nonrecently treated
control population, patients with nonrecently treated B-lymphoid
malignancies, recently treated control population, patients recently
treated for B-lymphoid malignancies) and cancer status (remission/
no evidence of disease, active/stable or responding to treatment,
active/progressing, unknown) to the primary analysis to investigate
differential effects.
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